Compile Data Set for Download or QSAR
Report error Found 62 Enz. Inhib. hit(s) with all data for entry = 11007
TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454204(US10717708, Example 188 | US11186544, Example 188 ...)
Affinity DataEC50:  0.130nMAssay Description:A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (200 μM final) were added to 384-well Proxiplates (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454192(US10717708, Example 86 | US11186544, Example 86 | ...)
Affinity DataEC50:  0.140nMAssay Description:A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (200 μM final) were added to 384-well Proxiplates (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454206(US10717708, Example 199 | US11186544, Example 199 ...)
Affinity DataEC50:  0.280nMAssay Description:A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (200 μM final) were added to 384-well Proxiplates (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454187(US10717708, Example 66 | US11186544, Example 66 | ...)
Affinity DataEC50:  0.320nMAssay Description:A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (200 μM final) were added to 384-well Proxiplates (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454196(US10717708, Example 145 | US11186544, Example 145 ...)
Affinity DataEC50:  0.360nMAssay Description:A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (200 μM final) were added to 384-well Proxiplates (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454202(US10717708, Example 183 | US11186544, Example 183 ...)
Affinity DataEC50:  0.460nMAssay Description:A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (200 μM final) were added to 384-well Proxiplates (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454202(US10717708, Example 183 | US11186544, Example 183 ...)
Affinity DataEC50:  0.560nMAssay Description:A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (200 μM final) were added to 384-well Proxiplates (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454189(US10717708, Example 77 | US11186544, Example 77 | ...)
Affinity DataEC50:  0.680nMAssay Description:A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (200 μM final) were added to 384-well Proxiplates (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454205(US10717708, Example 197 | US11186544, Example 197 ...)
Affinity DataEC50:  0.760nMAssay Description:A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (200 μM final) were added to 384-well Proxiplates (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454188(US10717708, Example 76 | US11186544, Example 76 | ...)
Affinity DataEC50:  0.810nMAssay Description:A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (200 μM final) were added to 384-well Proxiplates (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454190(US10717708, Example 78 | US11186544, Example 78 | ...)
Affinity DataEC50:  0.890nMAssay Description:A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (200 μM final) were added to 384-well Proxiplates (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454197(US10717708, Example 166 | US11186544, Example 166 ...)
Affinity DataEC50:  8nMAssay Description:A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (200 μM final) were added to 384-well Proxiplates (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454203(US10717708, Example 184 | US11186544, Example 184 ...)
Affinity DataEC50:  8.10nMAssay Description:A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (200 μM final) were added to 384-well Proxiplates (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454176(US10717708, Example 15 | US11186544, Example 15 | ...)
Affinity DataEC50:  8.40nMAssay Description:A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (200 μM final) were added to 384-well Proxiplates (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454189(US10717708, Example 77 | US11186544, Example 77 | ...)
Affinity DataEC50:  8.80nMAssay Description:A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (200 μM final) were added to 384-well Proxiplates (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454193(US10717708, Example 125 | US11186544, Example 125 ...)
Affinity DataEC50:  9nMAssay Description:A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (200 μM final) were added to 384-well Proxiplates (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454186(US10717708, Example 58 | US11186544, Example 58 | ...)
Affinity DataEC50:  9.20nMAssay Description:A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (200 μM final) were added to 384-well Proxiplates (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454177(US10717708, Example 16 | US11186544, Example 16 | ...)
Affinity DataEC50:  9.30nMAssay Description:A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (200 μM final) were added to 384-well Proxiplates (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454194(US10717708, Example 129 | US11186544, Example 129 ...)
Affinity DataEC50:  9.40nMAssay Description:A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (200 μM final) were added to 384-well Proxiplates (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454182(US10717708, Example 36 | US11186544, Example 36 | ...)
Affinity DataEC50:  9.70nMAssay Description:A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (200 μM final) were added to 384-well Proxiplates (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454188(US10717708, Example 76 | US11186544, Example 76 | ...)
Affinity DataEC50:  10nMAssay Description:A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (200 μM final) were added to 384-well Proxiplates (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454195(US10717708, Example 139 | US11186544, Example 139 ...)
Affinity DataEC50:  10nMAssay Description:A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (200 μM final) were added to 384-well Proxiplates (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454178(US10717708, Example 17 | US11186544, Example 17 | ...)
Affinity DataEC50:  10nMAssay Description:A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (200 μM final) were added to 384-well Proxiplates (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454191(US10717708, Example 82 | US11186544, Example 82 | ...)
Affinity DataEC50:  11nMAssay Description:A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (200 μM final) were added to 384-well Proxiplates (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454191(US10717708, Example 82 | US11186544, Example 82 | ...)
Affinity DataEC50:  14nMAssay Description:A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (200 μM final) were added to 384-well Proxiplates (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454196(US10717708, Example 145 | US11186544, Example 145 ...)
Affinity DataEC50:  15nMAssay Description:A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (200 μM final) were added to 384-well Proxiplates (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454204(US10717708, Example 188 | US11186544, Example 188 ...)
Affinity DataEC50:  25nMAssay Description:A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (200 μM final) were added to 384-well Proxiplates (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454192(US10717708, Example 86 | US11186544, Example 86 | ...)
Affinity DataEC50:  32nMAssay Description:A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (200 μM final) were added to 384-well Proxiplates (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454190(US10717708, Example 78 | US11186544, Example 78 | ...)
Affinity DataEC50:  42nMAssay Description:A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (200 μM final) were added to 384-well Proxiplates (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454187(US10717708, Example 66 | US11186544, Example 66 | ...)
Affinity DataEC50:  100nMAssay Description:A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (200 μM final) were added to 384-well Proxiplates (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454206(US10717708, Example 199 | US11186544, Example 199 ...)
Affinity DataEC50:  140nMAssay Description:A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (200 μM final) were added to 384-well Proxiplates (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454195(US10717708, Example 139 | US11186544, Example 139 ...)
Affinity DataEC50:  150nMAssay Description:A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (200 μM final) were added to 384-well Proxiplates (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454194(US10717708, Example 129 | US11186544, Example 129 ...)
Affinity DataEC50:  170nMAssay Description:A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (200 μM final) were added to 384-well Proxiplates (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454178(US10717708, Example 17 | US11186544, Example 17 | ...)
Affinity DataEC50:  170nMAssay Description:A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (200 μM final) were added to 384-well Proxiplates (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454176(US10717708, Example 15 | US11186544, Example 15 | ...)
Affinity DataEC50:  200nMAssay Description:A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (200 μM final) were added to 384-well Proxiplates (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454179(US10717708, Example 26 | US11186544, Example 26 | ...)
Affinity DataEC50:  210nMAssay Description:A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (200 μM final) were added to 384-well Proxiplates (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454205(US10717708, Example 197 | US11186544, Example 197 ...)
Affinity DataEC50:  220nMAssay Description:A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (200 μM final) were added to 384-well Proxiplates (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454182(US10717708, Example 36 | US11186544, Example 36 | ...)
Affinity DataEC50:  280nMAssay Description:A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (200 μM final) were added to 384-well Proxiplates (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454186(US10717708, Example 58 | US11186544, Example 58 | ...)
Affinity DataEC50:  280nMAssay Description:A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (200 μM final) were added to 384-well Proxiplates (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454197(US10717708, Example 166 | US11186544, Example 166 ...)
Affinity DataEC50:  330nMAssay Description:A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (200 μM final) were added to 384-well Proxiplates (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454183(US10717708, Example 47 | US11186544, Example 47 | ...)
Affinity DataEC50:  330nMAssay Description:A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (200 μM final) were added to 384-well Proxiplates (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454193(US10717708, Example 125 | US11186544, Example 125 ...)
Affinity DataEC50:  330nMAssay Description:A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (200 μM final) were added to 384-well Proxiplates (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454179(US10717708, Example 26 | US11186544, Example 26 | ...)
Affinity DataEC50:  380nMAssay Description:A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (200 μM final) were added to 384-well Proxiplates (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454177(US10717708, Example 16 | US11186544, Example 16 | ...)
Affinity DataEC50:  390nMAssay Description:A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (200 μM final) were added to 384-well Proxiplates (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454180(US10717708, Example 27 | US11186544, Example 27 | ...)
Affinity DataEC50:  400nMAssay Description:A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (200 μM final) were added to 384-well Proxiplates (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454198(US10717708, Example 174 | US11186544, Example 174 ...)
Affinity DataEC50:  450nMAssay Description:A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (200 μM final) were added to 384-well Proxiplates (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454199(US10717708, Example 175 | US11186544, Example 175 ...)
Affinity DataEC50:  520nMAssay Description:A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (200 μM final) were added to 384-well Proxiplates (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454181(US10717708, Example 28 | US11186544, Example 28 | ...)
Affinity DataEC50:  560nMAssay Description:A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (200 μM final) were added to 384-well Proxiplates (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454184(US10717708, Example 48 | US11186544, Example 48 | ...)
Affinity DataEC50:  560nMAssay Description:A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (200 μM final) were added to 384-well Proxiplates (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM454200(US10717708, Example 176 | US11186544, Example 176 ...)
Affinity DataEC50:  780nMAssay Description:A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (200 μM final) were added to 384-well Proxiplates (Perki...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
US Patent

Displayed 1 to 50 (of 62 total ) | Next | Last >>
Jump to: